Product information and disease description Place of product in therapy Approaches to treatment

Other product development or post-marketing obligations required by the FDA

10 evidence topics · 7 sources

Accelerated approval postmarketing requirement 4608-1: randomized confirmatory trial

“Conduct a multiregional, randomized clinical trial comparing tovorafenib to physician’s choice of chemotherapy in pediatric patients with low grade glioma with RAF fusions or rearrangements, or V600 mutations, intended to verify and describe the clinical benefit of tovorafenib through assessment of overall response rate (ORR) as a primary endpoint and progression-free survival (PFS) and duration of response, as determined by blinded independent central review, as key secondary endpoints.” (opens the source at this quote in a new tab)
“Include the protocol-specified ORR and interim PFS analyses in the interim report.” (opens the source at this quote in a new tab)

Accelerated approval postmarketing requirement 4608-1: timetable

Milestone	Date
Interim report submission	“04/2028”
Trial completion	“10/2031”
Final report submission	“04/2032”

FDA review: FIREFLY-2 as the trial to verify clinical benefit

“Verification of benefit will be based on results from a randomized trial of tovorafenib compared to standard of care chemotherapy in patients with pediatric LGG with a primary endpoint of ORR and a key secondary endpoint of PFS.” (opens the source at this quote in a new tab)
“The Applicant intends to submit efficacy data from FIREFLY-2, an ongoing, international, open-label, randomized (1:1) controlled trial comparing tovorafenib to standard of care chemotherapy as first line treatment in 400 patients who require systemic therapy for pediatric LGG.” (opens the source at this quote in a new tab)

“The Company continues its commitment to the pLGG community with the Phase 3 FIREFLY-2/LOGGIC randomized clinical trial evaluating tovorafenib as a potential front-line therapy compared to chemotherapy in patients aged 6 months to 25 years with pLGG, which it believes will satisfy certain post-marketing requirements to the FDA.” (opens the source at this quote in a new tab)

FDA listing of the confirmatory requirement in September 2026

“4608-1: Conduct a multiregional, randomized clinical trial comparing tovorafenib to physician’s choice of chemotherapy in pediatric patients with low grade glioma with RAF fusions or rearrangements, or V600 mutations, intended to verify and describe the clinical benefit of tovorafenib through assessment of overall response rate (ORR) as a primary endpoint and progression-free survival (PFS) and duration of response, as determined by blinded independent central review, as key secondary endpoints.” (opens the source at this quote in a new tab)
“4/30/2032” (opens the source at this quote in a new tab)

Postmarketing requirements under 505(o): long-term growth, development, and gonadal toxicity

“Conduct comprehensive safety analyses from clinical studies that further characterize the known serious risk of long-term adverse effects of tovorafenib on growth and development, including but not limited to growth plate abnormalities, in a sufficient number of pediatric patients.” (opens the source at this quote in a new tab)
“Monitor patients until discontinuation of study treatment or a minimum of 5 years from start of treatment, whichever occurs first.” (opens the source at this quote in a new tab)
“Conduct comprehensive safety analyses from clinical studies that further characterize the potential serious risk of gonadal toxicity in a sufficient number of adolescent and young adult patients treated with tovorafenib.” (opens the source at this quote in a new tab)

Postmarketing requirements under 505(o): carcinogenicity and drug interaction studies

“Conduct a carcinogenicity study in rats to evaluate the potential serious risk of carcinogenicity.” (opens the source at this quote in a new tab)
“Conduct a clinical pharmacokinetic trial of tovorafenib with a strong CYP2C8 inhibitor to evaluate the potential increased drug toxicity and provide dosage recommendations for tovorafenib when used concomitantly with strong and moderate CYP2C8 inhibitors.” (opens the source at this quote in a new tab)
“Conduct a clinical pharmacokinetic trial of multi-dose tovorafenib on substrates of BCRP to evaluate the potential for increased toxicity of BCRP substrates and provide appropriate drug interaction management strategies for tovorafenib when used concomitantly with BCRP substrates.” (opens the source at this quote in a new tab)

Postmarketing commitments: FIREFLY-1 follow-up and CYP2C8 inducer study

“Complete the FIREFLY-1 trial, including your planned additional follow-up for the 137 patients with relapsed or refractory low-grade glioma harboring a BRAF alteration enrolled to Arms 1 and 2 of FIREFLY-1 and treated with tovorafenib, to further characterize the overall response rate (ORR) and duration of response (DoR) as per Response Assessment in Pediatric Neuro-oncology (RAPNO) criteria including assessment by an independent review committee (IRC) for patients enrolled to Arm 1.” (opens the source at this quote in a new tab)
“Conduct a clinical pharmacokinetic trial with a strong or moderate CYP2C8 inducer with tovorafenib to evaluate the effect of a strong or moderate CYP2C8 inducer on decreasing the systemic exposure of tovorafenib and provide dosage recommendations for tovorafenib when used concomitantly with CYP2C8 inducers.” (opens the source at this quote in a new tab)

Fulfilled requirements and open accelerated approval requirement in August 2025

“We have reviewed your submissions and conclude that the above requirement/commitment were fulfilled.” (opens the source at this quote in a new tab)
“We remind you that accelerated approval PMR 4608-1 listed in the April 23, 2024, approval letter is still open.” (opens the source at this quote in a new tab)

European Union: specific obligations of the conditional marketing authorisation

“shall conduct and submit the final report of the phase III randomised, parallel-group, two-arm study (FIREFLY-2) to evaluate the efficacy and safety of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in patients with paediatric low-grade glioma harbouring an activating rapidly accelerated fibrosarcoma gene (RAF) alteration requiring first-line systemic therapy.” (opens the source at this quote in a new tab)
“The MAH shall generate additional PK data in paediatrics patients below 2 years of age and submit an updated population PK model incorporating these data, including an assessment of systemic exposure and, if necessary, revised dosing recommendations for this subgroup of patients.” (opens the source at this quote in a new tab)

European Union: CHMP view on FIREFLY-2 as the specific obligation

“the interim study report (including the ORR primary analysis and the PFS interim analysis) can be projected to be available for submission in April 2028, with the final study report planned for April 2032.” (opens the source at this quote in a new tab)
“In addition, while the study is conducted in a first-line setting, which differs from the second-line setting to be authorised under the CMA, the mechanism of action of Ojemda is not expected to be line-dependent, the molecular-defined disease target is consistent across treatment lines, and as explained, the study is expected to reduce key uncertainties identified at the time of the CMA.” (opens the source at this quote in a new tab)
“However, there is some uncertainty in the fact that this study excludes patients previously treated with dabrafenib in combination with trametinib.” (opens the source at this quote in a new tab)